58,76 €
3,41 % gestern
L&S, 30. Oktober, 22:54 Uhr
ISIN
NL0010696654
Symbol
QURE
Berichte

uniQure N.V. Aktie News

Positiv
Seeking Alpha
2 Tage alt
uniQure (QURE) is upgraded to Buy following strong 36-month high-dose AMT-130 data for Huntington's disease, showing significant slowing of disease progression. QURE's AMT-130 demonstrated robust clinical benefits, including improved daily activities, cognition, and motor function, despite small sample size and external control limitations. Financially, QURE is well-positioned with over $700 mi...
Positiv
MarketBeat
8 Tage alt
Momentum investors rely on a combination of astute analysis and timing to maximize gains. While this approach can carry a fair degree of risk, the allure of identifying a fast-growing stock and joining a rally that has room to continue is powerful.
Positiv
Seeking Alpha
22 Tage alt
uniQure surged over 300% following strong 3-year data from its Huntington's trial, yet remains undervalued due to skepticism over trial size and the use of external controls. AMT-130's apparent efficacy and prior alignment with the FDA on accelerated approval position AMT-130 for commercialization in the near term. Relatively modest volumes are needed to justify uniQure's current valuation, mea...
Positiv
MarketBeat
27 Tage alt
In one of the most incredible single-day moves this year, biotechnology stock uniQure NASDAQ: QURE surged by 284% on Sept. 24. This came as the firm released fantastic clinical results for its developmental medicine, AMT-130.
Neutral
GlobeNewsWire
etwa ein Monat alt
LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, which includes 947,368 ordinary s...
Neutral
GlobeNewsWire
etwa ein Monat alt
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 5,789,473 ordinary shares at a public offering price of $47.50 per share, and, in lieu of ordinary shares t...
Positiv
Forbes
etwa ein Monat alt
UniQure announced groundbreaking results for AMT-130, its gene therapy targeting Huntington's disease, showing a statistically significant 75% reduction in disease progression in a pivotal Phase I/II trial. ((UniQure's Press Release, Sep 24, 2025)) This milestone marks the first therapy to meaningfully slow Huntington's progression and positions UniQure to unlock value across revenue growth, ma...
Positiv
Market Watch
etwa ein Monat alt
A ClearPoint Neuro's medical device plays an important role in UniQure's effort to battle Huntington's disease.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen